# The Left Axillary Artery as an Alternative Inflow Source in Minimally Invasive Coronary Artery Bypass Grafting: Safety, Feasibility, and Mid-Term Outcomes

**Authors:** Jian Song, Tong Ding, Rui Li, Yichen Gong, Ruitao Zhang, Yuanhao Fu, Luyu Meng, Song Wu, Zhongqi Cui, Ya Wu, Chen Yang, Ming Cui, Yunpeng Ling

PMC · DOI: 10.3390/jcdd13020101 · Journal of Cardiovascular Development and Disease · 2026-02-21

## TL;DR

This study shows that using the left axillary artery as an alternative blood source in heart bypass surgery is safe and effective, with outcomes similar to traditional methods.

## Contribution

Demonstrates the left axillary artery as a viable alternative inflow source in minimally invasive coronary surgery.

## Key findings

- AXA group had comparable intraoperative hemodynamic performance to the ascending aorta group.
- Early graft occlusion rates were similar between AXA and ascending aorta groups.
- Mid-term survival and adverse event rates were not significantly different between the two groups.

## Abstract

Objective: The objective of this study is to evaluate the safety, feasibility, and mid-term outcomes of using the left axillary artery (AXA) as an alternative inflow source for the proximal anastomosis of the saphenous vein graft (SVG) in MICS-CABG, focusing on intraoperative graft haemodynamics, early patency, and clinical outcomes. Methods: We retrospectively analyzed consecutive patients who underwent MICS-CABG between April 2020 and August 2025 at a single center. Patients were divided into two groups based on the inflow source: the ascending aorta (n = 292) or the left axillary artery (n = 90). After propensity score matching, 80 matched pairs were analyzed. Intraoperative graft haemodynamics were assessed. Early graft patency was evaluated using coronary angiography or CT angiography. Mid-term outcomes, including overall survival and major adverse cardiac and cerebrovascular events (MACCEs), were compared between groups. Results: Both groups demonstrated comparable intraoperative hemodynamic performance. The AXA group demonstrated an early graft occlusion rate comparable to that of the AOR group (1.32% vs. 3.16%, RR = 0.42, 95% CI = 0.08–2.11, and p = 0.45). Overall survival (93.2% vs. 100%, p = 0.06) and the MACCE-free metric (91.9% vs. 92.1%, p = 0.83) showed no significant difference between groups. Conclusions: The left axillary artery is a safe and feasible alternative inflow source in MICS-CABG. This approach provides acceptable intraoperative flow dynamics, early patency, and mid-term outcomes to conventional ascending aortic inflow.

## Full-text entities

- **Diseases:** vascular stenosis (MESH:D003251), ischemia (MESH:D007511), shoulder joint weakness (MESH:D000070599), aortic valve disease (MESH:D000082862), postoperative stroke (MESH:D020521), rupture (MESH:D012421), diabetes (MESH:D003920), calcification (MESH:D002114), chronic kidney disease (MESH:D051436), aortic disease (MESH:D001018), hyperlipemia (MESH:D006949), injury to (MESH:D014947), brachial plexus injury (MESH:D020516), atheroma (MESH:D058226), heart failure (MESH:D006333), embolic (MESH:D004617), ascending aorta (MESH:D000094630), atrial fibrillation (MESH:D001281), COVID-19 (MESH:D000086382), cerebral infarction (MESH:D002544), MI (MESH:D009203), MACCEs (MESH:D002318), CKD (MESH:D012080), numbness (MESH:D006987), cardiac and cerebrovascular (MESH:D002561), atherosclerosis (MESH:D050197), -limb sensory abnormalities (MESH:D001259), hypertension (MESH:D006973), occlusion (MESH:D001157), death (MESH:D003643), shoulder, elbow, or wrist motion impairment (MESH:D000092503)
- **Chemicals:** cholesterol (MESH:D002784), Tc (MESH:D013667), creatinine (MESH:D003404), Cr (MESH:D002857)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940880/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940880/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940880/full.md

---
Source: https://tomesphere.com/paper/PMC12940880